

ASX ANNOUNCEMENT**ADMEDUS TO SHOWCASE CARDIOCEL[®] AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) ANNUAL MEETING**

- **Key Sponsor of Techno-College, 11th October, 2014**
- **Exhibiting at booth #123, 12th - 14th October, 2014**
- **Admedus hosting CardioCel[®] Satellite Symposium, 13th October, 2014**

Brisbane, Australia, 10th October, 2014

Admedus Limited (ASX:AHZ) announced today its attendance at the European Association for Cardio-Thoracic Surgery (EACTS) 28th Annual Meeting to be held in Milan from the 11th -15th October, 2014.

Admedus will be showcasing CardioCel[®], its advanced cardiovascular scaffold currently marketed in Europe and the US, at its booth and at a number of presentations and symposia. Following CE marking and FDA 510k clearance, CardioCel[®] is seeing increasing adoption as the tissue of choice for the repair of congenital heart deformities, more complex heart defects and heart valve repair procedures.

CardioCel[®] clinical data will feature on Saturday, 11th October at the Admedus sponsored Techno-College, where Admedus will also have an exhibition booth. The Annual Techno-College is an integral part of EACTS and provides an update on the latest developments in the field of cardiovascular, thoracic and congenital surgery.

Admedus will be exhibiting at booth #123 in the main hall from Sunday evening until Tuesday evening. A wet lab will be set up in the booth for hands-on CardioCel[®] product demonstrations.

The CardioCel[®] Satellite Symposium will take place from 12:45 – 14:00 on Monday, 13th October at the Milano Congressi in room Amber 6. Chaired by Prof. Mark Hazekamp, LUMC, The Netherlands, the symposium will comprise surgeon presentations and an open forum on the CardioCel[®] scaffold tissue engineering process and clinical usage to date. Panellists include:

- Prof. William Neethling, University of Western Australia;
- Prof. Tom Karl, Mater Children's Hospital, Brisbane;
- Mr Olivier Ghez, Royal Brompton Hospital, London; and
- Assoc.Prof. Geoffrey Strange, Admedus.

Follow us on Twitter: @Admedus and on Facebook:
www.facebook.com/pages/Admedus

For more information, please contact:

Dr. Julian Chick, Chief Operating Officer, Admedus Limited
Tel: +61 3 9620 5454

Australian Media:
Kyahn Williamson
Buchan Consulting
+61 3 8866 4722
kwilliamson@buchanwe.com.au

Media relations Europe & Asia
Consilium Strategic Communications
Emma Thompson / Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com

About CardioCel[®]

CardioCel[®] is a new type of cardiovascular scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is engineered via Admedus' proprietary ADAPT[™] tissue engineering process to produce a durable collagen scaffold with handling properties preferred by surgeons that avoids calcification while supporting native cell infiltration, growth and differentiation.

About EACTS

The mission of the European Association for Cardio-Thoracic Surgery is to advance education in the field of cardiac, thoracic and vascular interventions and promote research into cardiovascular and thoracic physiology, pathology and therapy, with the aim to correlate and disseminate the results for the public benefit

The EACTS Annual Meeting is the largest cardio-thoracic meeting in the world focusing on scientific developments and research in the following specialties: Acquired Cardiac Disease, Congenital Heart Disease, Vascular Disease and Thoracic Disease.

Further information on the EACTS Annual Meeting can be found on www.eacts.org/annual-meeting